RNA Editing Across Adipose Cell Types: Mechanisms, Clinical Implications, and Therapeutic Opportunities

Abstract

RNA editing, a post-transcriptional regulatory mechanism, introduces nucleotide modifications to RNA molecules, thereby diversifying the transcriptome and proteome without altering the underlying DNA. In adipose tissue, which comprises heterogeneous cell populations such as white, brown, beige adipocytes, preadipocytes, and stromal vascular cells, RNA editing has emerged as a crucial modulator of cellular identity, metabolic function, and disease susceptibility. This review synthesizes current evidence on RNA editing across adipose cell types, detailing its enzymatic basis, distribution, and clinical significance, while highlighting emerging therapeutic prospects.

Introduction

Adipose tissue is a dynamic endocrine organ with critical roles in energy homeostasis, insulation, and metabolic regulation. Beyond classical gene expression, the intricate regulation of adipose tissue function also involves epigenetic and post-transcriptional mechanisms, among which RNA editing is increasingly recognized. The main forms of RNA editing in mammals adenosine-to-inosine (A-to-I) catalyzed by ADAR enzymes and cytidine-to-uridine (C-to-U) mediated by APOBEC family members are differentially expressed and functionally relevant across adipose cell types. Understanding the landscape of RNA editing in adipose tissue is essential for elucidating mechanisms underlying metabolic health and disease.

Epidemiology / Disease Burden

Obesity and its associated metabolic disorders, including type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic fatty liver disease, represent a global health crisis. The prevalence of obesity has tripled worldwide since 1975, with over 650 million adults affected as of 2016. Adipose tissue dysfunction, driven by impaired cellular differentiation and maladaptive signaling, is central to the pathogenesis of these conditions. Recent transcriptomic studies reveal that aberrant RNA editing patterns are prevalent in adipose tissue of obese individuals, correlating with metabolic dysfunction, inflammation, and insulin resistance, thus representing a novel layer of disease burden in metabolic health.

Pathophysiology

RNA editing modifies the nucleotide sequence of RNA transcripts post-transcriptionally, affecting coding sequences, splicing, miRNA targeting, and RNA stability. In adipose tissue, A-to-I editing is mediated by ADAR1 and ADAR2, with expression levels varying between white and brown adipocytes. Editing events can alter the coding potential of key metabolic genes, such as those involved in lipid metabolism (e.g., APOB, GPD1) and mitochondrial function. Beyond coding regions, editing in untranslated regions (UTRs) and noncoding RNAs influences gene expression networks critical for adipocyte differentiation and function. Dysregulated RNA editing can disrupt adipocyte signaling, contribute to chronic inflammation, and promote adipose tissue fibrosis.

Risk Factors

Risk factors for aberrant RNA editing in adipose cells include genetic polymorphisms in ADAR or APOBEC genes, chronic inflammation, oxidative stress, and metabolic overload. Environmental influences such as high-fat diets, sedentary lifestyle, and exposure to obesogenic toxins may perturb the expression and activity of RNA editing enzymes. Epigenetic modifications, including DNA methylation and histone acetylation, also modulate the accessibility of editing machinery to target transcripts, further influencing editing efficiency and fidelity in various adipose cell types.

Clinical Features

Clinically, altered RNA editing patterns in adipose tissue are associated with phenotypic features of metabolic syndrome, including central obesity, insulin resistance, dyslipidemia, and low-grade inflammation. For example, decreased A-to-I editing in white adipose tissue correlates with impaired thermogenesis and increased visceral adiposity. Inflammatory adipose microenvironments exhibit upregulated RNA editing in pro-inflammatory cytokine transcripts, which may exacerbate chronic inflammation and metabolic derangements. These molecular signatures have potential utility as biomarkers for metabolic risk stratification and disease progression monitoring.

Diagnosis

The diagnosis of RNA editing alterations in adipose tissue relies on high-throughput sequencing technologies, primarily RNA-seq coupled with computational pipelines designed to distinguish genuine editing events from single nucleotide polymorphisms. Quantitative PCR and Sanger sequencing can validate specific editing sites. Recent advances in single-cell transcriptomics enable the resolution of cell type-specific editing landscapes, facilitating the identification of editing signatures associated with distinct adipose cell populations and disease states. These molecular diagnostics are not yet routine in clinical practice but hold promise for personalized metabolic profiling.

Treatment & Management

While direct modulation of RNA editing in adipose tissue is not yet a standard therapeutic approach, existing interventions targeting metabolic health such as lifestyle modification, pharmacotherapy (e.g., metformin, GLP-1 receptor agonists), and bariatric surgery may indirectly influence RNA editing patterns by ameliorating inflammatory and metabolic stress. Future therapeutic strategies may involve small molecules or antisense oligonucleotides designed to modulate ADAR or APOBEC enzyme activity, or to correct specific pathogenic editing events in key metabolic genes, thereby restoring adipose function and systemic energy balance.

Recent Advances / Emerging Therapies

Recent research has illuminated the cell-type specificity of RNA editing across adipose depots and the regulatory influence of editing on noncoding RNAs, such as microRNAs and long noncoding RNAs, which orchestrate adipogenic differentiation and thermogenic programming. Novel RNA-based therapeutics such as engineered ADAR-recruiting guide RNAs demonstrate proof-of-concept correction of pathogenic editing events in preclinical models. Additionally, genome-wide association studies are unraveling links between editing enzyme variants and susceptibility to obesity-related diseases, paving the way for precision medicine approaches targeting the RNA editome in adipose tissue.

Guideline Recommendations

Current clinical guidelines for the management of obesity and metabolic syndrome do not specifically address RNA editing; however, expert consensus underscores the importance of comprehensive metabolic profiling, which may soon integrate RNA editing biomarkers. Ongoing research and future guideline updates are likely to incorporate molecular diagnostics and targeted RNA editing interventions as evidence continues to accumulate regarding their clinical utility and safety.

Conclusion

RNA editing represents a critical layer of post-transcriptional regulation in adipose tissue biology, influencing cell type identity, metabolic function, and disease susceptibility. Advances in sequencing technologies and molecular therapeutics are rapidly expanding our understanding of the adipose RNA editome and its clinical relevance. Further research is warranted to elucidate the mechanistic roles of specific editing events, to validate editing-based biomarkers, and to develop targeted interventions that harness RNA editing for the prevention and treatment of metabolic diseases.